Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 2Sarcoma 1Osteosarcoma 1Melanoma 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Bone Neoplasms 1

Interventions

Cyclophosphamide 3regorafenib 2Proton Therapy 2Methods 2Gemcitabine 2Doxorubicin 2tocilizumab 1poly ICLC 1pembrolizumab 1liposomal doxorubicin 1lenvatinib 1fludarabine 1flt3 ligand protein 1endostar protein 1alectinib 1aldesleukin 1Weight-Bearing 1Transcranial Direct Current Stimulation 1Taxes 1Surveys and Questionnaires 1Standard of Care 1Restraint, Physical 1Range of Motion, Articular 1Radiotherapy 1Radiosurgery 1Radiation 1Quality of Life 1Psychology, Positive 1Platinum 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Neoplasms × flt3 ligand protein × 1 year × Clear all
NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡